Three of the 8 non-responder patients had a monoallelic BRCA2 shallow deletion, and one had a shallow deletion of BRCA2, combined with a variant of uncertain significance of BRCA2. Grade 3–4 adverse events were comparable to the previous PARPi studies (i.e., anemia 24%, lymphopenia 12% and nausea 12%). This evidence concerns the gene BRCA2 and anemia (phenotype).